GlassScriptPrepare for your visit
Sathish Kumar Kumar Krishnan
Pulmonary Disease · Indianapolis, IN · NPI 1508121492
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$5,203.95
in general payments reported to CMS, 2019-2025 · $1,020 in 2025
The $1,020 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Who reported paying
General payments only, top 6 by amount.
- Olympus Corporation of The Americas $1,595.18
- Glaxosmithkline, LLC. $441.18
- Boehringer Ingelheim Pharmaceuticals, INC. $336.46
- Jazz Pharmaceuticals INC. $276.34
- Grifols USA, LLC $238.01
- Boston Scientific Corporation $206.53
Drugs and devices associated with these payments
Single Use Suction Valve (Sterile) Prolastin-C Liquid Ekosonic Teflaro Xywav Dalvance Ofev Avycaz Dupixent Yupelri Nucala Trelegy Ellipta
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Sathish Kumar Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/340855/sathish-kumar-kumar-krishnan